| Gene name: | RBM38 |
| Aging type: | Prevent |
| Aging characteristic: |
| Tissue type: | -- |
| Cell name: | MEF |
| Experiment: | SA-β-gal activity assay//Knockdown |
| Description: | We showed that the number of cells stained positive with senescence-associated β-galactosidase (SA-β-gal) was markedly increased by lack of RNPC1 regardless of DNA damage . Quantitative analysis indicated that SA-β-gal-positive cells were increased by threefold to eightfold upon loss of RNPC1 (47.5% in RNPC1?/? MEFs vs. 5.5% in RNPC1+/+ MEFs and 6.5% in RNPC1+/? MEFs in the absence of doxorubicin; 64.5% in RNPC1?/? MEFs vs. 18% in RNPC1+/+ MEFs and 19.5% in RNPC1+/? MEFs in the presence of doxorubicin). |
| Regulatory pathway: | P53 |
| R-AG-Pathway: | Downregulation |
| Official symbol(s): | TP53 |
| Pathway experiment: | Western blot |
| Pathway description: | We showed that p53 was highly induced by RNPC1 deficiency, especially upon treatment with doxorubicin, consistent with the observation. Similarly, transient expression of RNPC1a, but not RNPC1b, inhibited p53 expression in a dose-dependent manner. Furthermore, we showed that upon treatment with doxorubicin or nutlin-3, ectopic expression of RNPC1a markedly attenuated p53 accumulation in MCF7 and RKO cells . |
Annotation:
Loading,please wait...